Navigation Links
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Date:8/2/2009

foundation for achieving our long-term goal of becoming a fully integrated specialty pharmaceutical company and creating even greater value for our shareholders."

Purdue's President and Chief Executive Officer, John H. Stewart commented, "We are excited to be working with Transcept towards the launch of this potential new entry into the prescription sleep aid market. This agreement is part of Purdue's plan to diversify our product portfolio and broaden our commercial focus into therapeutic areas that complement our leadership position in pain management." Mr. Stewart added, "We are confident that prescribers will find Intermezzo((R)) to be a valuable therapeutic option for managing patients with middle-of-the-night sleep disorders that fall within the proposed indication for the product's use."

About Intermezzo((R))

Intermezzo((R)) (zolpidem tartrate sublingual tablet) has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo((R)) is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the United States for the treatment of insomnia. Intermezzo((R)) uses approximately one-quarter to one-third of the dose of active drug contained in currently marketed zolpidem-based sleep aids, in a formulation designed to promote rapid sublingual absorption. Transcept believes that Intermezzo((R)), by combining the reduced zolpidem dose with administration only on those nights when a middle of the night awakening actually occurs, has the potential to reduce unnecessary sedative-hypnotic exposure.

Two Phase 3 clinical studies evaluated 376 patients receiving either Intermezzo((R)) or placebo. In the first study, a sleep laboratory trial using an objective polysomnographic end
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.; Purdue Pharmaceutical Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Purdue creating wireless sensors to monitor bearings in jet engines
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
4. Purdue researcher invents molecule that stops SARS
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Now available is a stem ... Rehealth Regenerative Therapies , located in Guadalajara, ... active people a new health option: stem cell ... age, countless patients suffer from joint and muscle injuries ... muscle tears, torn rotator cuff, tennis elbow, and knee ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... LANSING, Mich. , July 24, 2014  Neogen ... today that future forecasts of its potential revenue from ... conference call to investors and analysts on July 22, ... questioned by analysts regarding this research. "It ... answer questions about the potential of a new type ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2
... Bacterin International Holdings, Inc. (NYSE Amex: BONE ... material and anti-infective coatings for medical applications, achieved its most ... greater capacity and efficiency in the company,s operational platform, which ... reorganization completed during the month. "As our ...
... Scientists can make graphene out of just about anything with carbon ... Rice University lab of chemist James Tour proved it when they ... show them how it,s done. The work is part of ... scientists described how graphene -- a single-atom-thick sheet of the same ...
... 2011 Interleukin Genetics, Inc. (OTCQB: ILIU) announced ... on Friday, August 12 at 9:30 a.m. EDT to discuss ... live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live ... on the Investors section of Interleukin Genetics, Inc.,s Website at ...
Cached Biology Technology:Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 2Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 3Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 4Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 5Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 6One box of Girl Scout Cookies worth $15 billion 2Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results 2
(Date:7/25/2014)... (NRG1) is a pleiotropic factor characterized by the ... of exons that confer to the protein deeply ... both the myelination occurring during development and the ... nerve: axon degeneration, axon regrowth, remyelination and target ... have discovered that the soluble NRG1 upregulation observed ...
(Date:7/25/2014)... study shows that the age girls reach puberty is influenced ... on which parent contributes the gene. This is the ... development after birth and details of this study were published ... the first period, known as menarche, is a marker for ... that the onset of menses varies between girls, is an ...
(Date:7/25/2014)... the first time, Spanish researchers have detected an unknown ... cells are introduced into a droplet of salt ... sodium chloride crystallisation to create biomineralogical biosaline 3D morphologically ... the material, bacteria are revived. The discovery was made ... the cover of the Astrobiology journal and ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Bacteria manipulate salt to build shelters to hibernate 2
... DANVILLE, Pa. and PITTSBURGH , July 8 ... status of medication delivery through the use of Aethon,s MedEx system, ... , , , ... the functionality of Aethon,s TUG robots, automatic robotic delivery devices that ...
... by 2050 to address rising population and demand, new ... will suffer unless new approaches to adapt crop plants ... for the remarkable increases in yield accomplished during the ... of the world,s most important crops. "Global ...
... New Orleans, LA Patricia Molina, MD, PhD, Professor ... Orleans, has been awarded a $4 million grant over five ... National Institutes of Health to study how cannabinoids, the principal ... that affect how a person responds to HIV infection. ...
Cached Biology News:Geisinger Implements MedEx System to Enhance Medication Delivery, Tracking 2Geisinger Implements MedEx System to Enhance Medication Delivery, Tracking 3'Business as usual' crop development won't satisfy future demand 2'Business as usual' crop development won't satisfy future demand 3
... compatible with ABI thermal cyclers, QPCR instruments ... characteristics can be sealed with heat ... Certified free of DNase, RNase and human ... Fisher Scientific, the world leader in serving ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
BD BioCoat Vented Caps for 175 cm2 Flasks...
...
Biology Products: